I wouldn't say "very poor". Still an increase in revenue. Big increase in marketing and business development costs but I thought that would have been in preparation for the US launch of Remplir. Sure, a bigger increase in revenue would have been better and that could be disappointing. However, "very poor" is a bit harsh, imo. For me, the critical point will be the initial US Remplir revenues in the next quarter and, even moreso, in the following quarter when we have a whole quarter of sales, not just a part quarter. Just my thoughts.
- Forums
- ASX - By Stock
- OCC
- Ann: Quarterly Activity Report & Appendix 4C
OCC
orthocell limited
Add to My Watchlist
2.40%
!
$1.22

Ann: Quarterly Activity Report & Appendix 4C, page-13
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.22 |
Change
-0.030(2.40%) |
Mkt cap ! $295.6M |
Open | High | Low | Value | Volume |
$1.26 | $1.26 | $1.22 | $267.2K | 215.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5157 | $1.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.22 | 52574 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 5280 | 1.215 |
2 | 30500 | 1.210 |
3 | 17367 | 1.205 |
5 | 44749 | 1.200 |
1 | 4867 | 1.195 |
Price($) | Vol. | No. |
---|---|---|
1.220 | 52574 | 3 |
1.225 | 13090 | 3 |
1.230 | 3244 | 1 |
1.235 | 12879 | 3 |
1.240 | 15691 | 3 |
Last trade - 11.49am 30/06/2025 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online